Regulatory scrutiny will prevent drug plans managers from holding down costs for consumers
As drug coverage increases as a result of expanded health insurance and Medicaid coverage under the Patient Protection and Affordable Care Act, unnecessary regulations will increase prescription drug costs, according to a study from the National Center for Policy Analysis (NCPA).
“Sixty percent of all Americans take a prescription drug in any given year, and nearly all seniors do,” says NCPA Senior Fellow Devon Herrick. “Drug coverage is expanding rapidly and heightened regulatory scrutiny will prevent drug plan managers from holding down costs for consumers with programs such as creating exclusive networks and encouraging mail-order prescriptions.”
Herrick reviewed economic and policy literature on drug plans, as well as the literature on lobbying and government documents.
“The basic findings are that some of the regulations purported to benefit consumers actually harm them by driving up costs,” Herrick says. “Something implied but maybe not stated is special interests often promote legislation as beneficial ‘consumer protections’ that is actually designed to benefit special interests.”
Herrick says there are many barriers, regulations and practices that restrict competitive bidding among drug plan stakeholders.
“Regulations that inhibit the negotiation process between drug-makers, drug stores, and the drug plan will affect managed care organizations that insure health plan enrollees,” he says.
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Addressing the Barriers of Medication Adherence Through Digital Health
July 9th 2023Tony Little, ND, VP of Solutions Architecture at Prescryptive Health, shares how the organization is tackling one of the biggest barriers to prescription adherence — cost — through a digital app, among the other barriers patients face.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen